PTK7 and GPC Coreceptor Blocking in CCN2 Signaling

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The existing understanding of CCN protein signaling mechanisms is incomplete, lacking well-characterized reagents and evidence for receptor complexes, necessitating the identification of receptors responsible for transmitting CCN signaling responses, particularly for treating diseases associated with CCN ligand-induced signaling such as fibrosis and cancer.

Innovation Solution

Identifying PTK7 as a signaling receptor for C-terminal CCN2 and GPCs as coreceptors, developing agents that bind to PTK7, inhibit PTK7 expression, or interfere with GPC-CCN ligand-PTK7 complex formation to block CCN ligand-induced signaling, thereby treating diseases like fibrosis, metabolic disorders, and cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CCN protein signaling mechanisms are studied using existing reagents, then research can proceed with available tools, but the understanding remains incomplete due to lack of well-characterized reagents and evidence for receptor complexes

Engineering Contradiction:

Improvecompleteness of signaling mechanism understandingVSAvoidcomplexity of receptor complex identification

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses a multi-step assay system with intermediary components: first using domain IV fragments to identify potential receptors, then using full-length CCN proteins to confirm binding, and finally employing co-immunoprecipitation to characterize complex formation. This intermediary approach systematically builds evidence for receptor complexes without requiring complete characterization at each step simultaneously.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent segments the CCN protein into functional domains (domain IV containing the active site, and full-length protein) to systematically identify receptor binding. By testing domain fragments first, the invention isolates the critical signaling region and identifies specific receptor interactions, then confirms these interactions with full-length proteins, thereby systematically building complete understanding of the signaling mechanism.

Inventive Principle:

Principle #1Segmentation

2Object-affected harmful factors

If agents are developed to inhibit PTK7 activity or expression, then harmful CCN ligand-induced signaling can be blocked, but the complexity of identifying and characterizing effective agents increases

Engineering Contradiction:

Improveharmful signaling in fibrosis and cancerVSAvoidease of agent development and characterization

Core Design Contradiction:

Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The patent extracts and characterizes specific functional domains (domain IV) of CCN proteins to identify critical receptor binding regions. By focusing on this extracted domain, the invention simplifies the identification of receptor interactions and enables systematic screening for inhibitory agents that target this specific binding interface, thereby reducing the complexity of agent development while maintaining therapeutic effectiveness.

Inventive Principle:

Principle #2Taking out (Extraction)

3Adaptability or versatility

If the modular protein paradigm is applied to CCN proteins, then each domain can be studied independently, but evidence for this hypothesis is lacking due to technical challenges with reagents and reproduction

Engineering Contradiction:

Improveindependent domain functionalityVSAvoidreproducibility of domain activity evidence

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent employs domain IV fragments as intermediary molecules to test the modular hypothesis. By first characterizing binding of this isolated domain to potential receptors, then confirming with full-length proteins, the invention creates a reproducible intermediate step that validates domain independence while maintaining connection to full-protein functionality, thereby providing reliable evidence for modular action.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260041702A1Agents that inhibit CCN ligand-induced signalling for treating disease

Publication Date: 2026.02.12 TRIBUNE THERAPEUTICS AB

AI summary

The invention is based in part on the identification of PTK7 as a signalling receptor for C-terminal (domains III-IV) CCN2, and in part on the finding that GPC-1 and GPC-4 may act (individually or in combination) as coreceptors for CCN ligands. The invention relates to the therapeutic use of agents that bind to PTK7 and have PTK7 antagonist activity, agents that inhibit expression of PTK7, agents comprising a PTK polypeptide or a fragment thereof, agents that bind to a GPC coreceptor for CCN ligand and thus inhibit formation of GPC-CCN ligand-PTK7 complexes, agents that inhibit expression of GPCs. or agents comprising a GPC polypeptide or fragment thereof. The invention also relates to pharmaceutical compositions comprising such agents, and screening methods for their identification.